Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 821-823

  Higgins, Paul G ^a   Wisplinghoff, Hilmar ^a   Stefanik, Danuta ^a   Seifert, Harald ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Ciprofloxacin; Efflux; Multidrug resistance; RT PCR

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; MEROPENEM; MESSENGER RNA; NETILMICIN; OFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; EPIDEMIC; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC SELECTION; GENETIC TRANSCRIPTION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CROSS INFECTION; DISEASE OUTBREAKS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 6344222032     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh427     Document Type: Article

References (10)

1. Jawad, A., Seifert, H., Snelling, A. M. et al. (1998). Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates. Journal of Clinical Microbiology 36, 1938-41.
2. Koeleman, J. G. M., van der Bijl, M. W., Stoof, J. et al. (2001). Antibiotic resistance is a major risk factor for epidemic behavior of Acinetobacter baumannii. Infection Control and Hospital Epidemiology 22, 284-8.
3. Paterson, D. L. (2004). "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clinical Infectious Diseases 38, S341-5.
4. Villers, D., Espaze, E., Coste Burel, M. et al. (1998). Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Annals of Internal Medicine 129, 182-9.
5. Magnet, S., Courvalin, P. & Lambert, T. (2001). Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrobial Agents and Chemotherapy 45, 3375-80.
6. Seifert, H. & Gerner Smidt, P. (1995). Comparison of ribotyping and pulsed-field gel-electrophoresis for molecular typing of Acinetobacter isolates. Journal of Clinical Microbiology 33, 1402-7.
7. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA.
8. Vila, J., Ruiz, J., Goni, P. et al. (1997). Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 39, 757-62.
9. Davidson, R., Cavalcanti, R., Brunton, J. L. et al. (2002). Brief report: resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
10. Jalal, S., Ciofu, O., Hoiby, N. et al. (2000). Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 44, 710-2.